RecruitingNCT04539301

Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels

Sponsor

Nantes University Hospital

Enrollment

2,100 participants

Start Date

Apr 1, 2021

Study Type

OBSERVATIONAL

Conditions

Atrial Fibrillation Venous Thromboembolism Anticoagulation

Summary

Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitors-specific assays are scarcely available, contrary to heparin anti-Xa assay. The investigators aimed at assessing whether the widely used heparin anti-Xa assay can quantify the apixaban, rivaroxaban, fondaparinux and danaparoid levels.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is validating a single standardized lab test that can accurately measure the blood levels of four different blood-thinning medications — apixaban, rivaroxaban, danaparoid, and fondaparinux — which are used to prevent or treat blood clots. **You may be eligible if...** - You are an adult patient currently taking one of four specific blood thinners: apixaban (Eliquis), rivaroxaban (Xarelto), danaparoid, or fondaparinux - A blood sample is being collected as part of your routine care **You may NOT be eligible if...** - You are taking unfractionated heparin or low molecular weight heparin (such as enoxaparin/Lovenox) instead of the above medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.